Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: An enigma and an opportunity

Expert Review of Anticancer Therapy

Volumn 12, Issue 1, 2012, Pages 121-128

  Costello, Leslie C ^a,b   Franklin, Renty B ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

cancer chemotherapy; Clioquinol; prostate cancer; zinc; zinc ionophore; ZIP transporters

Indexed keywords

CLIOQUINOL; ZINC; ZINC TRANSPORTER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CANCER THERAPY; CELL PROTECTION; CHORIOCARCINOMA; COLON CANCER; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ESOPHAGUS CANCER; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; TONGUE CANCER; TUMOR VASCULARIZATION; ZINC BLOOD LEVEL; ZINC METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; ZINC;

EID: 83455212195     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.190     Document Type: Review

References (47)

1. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol. Cancer 5, 17 (2006).
2. Franklin RB, Milon B, Feng P, Costello LC. Zinc and zinc transporter in normal prostate function and the pathogenesis of prostate cancer. Front. Biosci. 10, 2230-2239 (2005).
3. Costello LC, Franklin RB, Feng P, Tan M, Bagasra O. Zinc and prostate cancer: a critical scientific, medical and public interest issue. Cancer Causes Contr. 16, 901-915 (2005).
4. Danielsen A, Steinnes E. A study of some selected trace elements in normal and cancerous tissue by neutron activation analysis. J. Nucl. Med. 11, 260-264 (1970).
5. Ebara M, Fukuda H, Hatano R et al. Relationship between copper, zinc and metallothionein in hepatocellular carcinoma and its surrounding liver parenchyma. J. Hepatol. 33, 415-422 (2000).
6. Gurusamy K. Trace element concentration in primary liver cancers -a systematic review. Biol. Trace Elem. Res. 118, 191-206 (2007).
7. Liaw KY, Lee PH, Wu FC, Tsai JS, Lin-Shiau SY. Zinc, copper, and superoxide dismutase in hepatocellular carcinoma. Am. J. Gastroenterol. 92, 2260-2263 (1997).
8. Tashiro H, Kawamoto T, Okubo T, Koide O. Variation in the distribution of trace elements in hepatoma. Biol. Trace Elem. Res. 95, 49-63 (2003).
9. Tashiro-Itoh T, Ichida T, Matsuda Y et al. Metallothionein expression and concentrations of copper and zinc are associated with tumor differentiation in hepatocellular carcinoma. Liver 17, 300-306 (1997).
10. Al-Ebraheem A, Farquharson MJ, Ryan E. The evaluation of biologically important trace metals in liver, kidney and breast tissue. Appl. Radiat. Isot. 67, 470-474 (2009).
11. Franklin RB, Levy BA, Zou J et al. ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer. J. Gastrointest. Cancer doi:10.1007/s12029-011-9269-x (2011) (Epub ahead of print).
12. Costello LC, Levy B, Desouki M et al. Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma. Cancer Biol. Ther. 12, 297-303 (2011).
13. Lightman A, Brandes JM, Binur N, Drugan A, Zinder O. Use of the serum copper/zinc ratio in the differential diagnosis of ovarian malignancy. Clin. Chem. 32, 101-103 (1986).
14. Costello LC, Fensaleu C, Franklin RB. Evidence for operation of the direct zinc ligand exchange mechanism for trafficking, transport, and reactivity of zinc in mammalian cells. J. Inorg. Biochem. 105, 589-599 (2011).
15. Mawson CA, Fischer MI. The occurrence of zinc in the human prostate gland. Can. J. Med. Sci. 30, 336-339 (1952).
16. Franklin RB, Feng P, Milon BC et al. hZIP1 zinc uptake transporter downregulation and zinc depletion in prostate cancer. Mol. Cancer 4, 32 (2005).
17. Johnson LA, Kanak MA, Kajdacsy-Balla A, Pestaner JP, Bagasra O. Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands. Methods 4, 316-321 (2010).
18. Cortesi M, Fridman E, Volkov A et al. Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needle-biopsy study. Prostate 68, 994-1006 (2008).
19. Franklin RB, Costello LC. The important role of the apoptotic effects of zinc in the development of cancers. J. Cell Biochem. 106, 750-757 (2009).
20. Costello LC, Franklin RB. The genetic/metabolic transformation concept of carcinogenesis. Cancer Metastasis Rev. doi:10.1007/s10555-011-9334-8. (2011) (Epub ahead of print).
21. Feng P, Li T, Guan Z, Franklin RB, Costello LC. Effect of zinc on prostate tumorigenicity in nude mice. Ann. NY Acad. Sci. 1010, 316-320 (2003).
22. Costello LC, Liu L, Zou J, Franklin RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J. Biol. Chem. 274, 17499-17504 (1999).
23. Franklin RB, Ma J, Zou J et al. Human Zip1 is a major zinc uptake transporter for accumulation of zinc in prostate cells. J. Inorgan. Biochem. 96, 435-442 (2003).
24. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res. 65, 3389-3395 (2005).
25. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol. Rev. 73, 79-118 (1993).
26. Jayaraman AK, Jayaraman S. Increased level of exogenous zinc induces cytotoxicity and up-regulates the expression of the ZnT-1 zinc transporter gene in pancreatic cancer cells. J. Nutr. Biochem. 22, 79-88 (2011).
27. Sliwinski T, Czechowska A, Kolodziejczak M, Jajte J, Wisniewska- Jarosinska M, Blasiak J. Zinc salts differentially modulate DNA damage in normal and cancer cells. Cell Biol. Int. 33, 542-547 (2009).
28. Liang, J Y, Liu YY, Zou J, Franklin RB, Costello LC, Feng P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 40, 200-207 (1999).
29. Feng P, Li L, Guan ZX, Franklin RB, Costello LC. Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 52, 311-318 (2002).
30. Feng P, Li T, Guan Z, Franklin RB, Costello LC. The involvement of Bax in zinc-induced mitochondrial apoptogenesis in malignant prostate cells. Mol. Cancer 7, 25 (2008).
31. Ku JH, Seo SY, Kwak C, Kim HH. The role of survivin and Bcl-2 in zinc-induced apoptosis in prostate cancer cells. Urol. Oncol. doi:10.1016/j.urolonc.2010.06.001 (2010) (Epub ahead of print).
32. Park SE, Park JW, Cho YS, Ryu JH, Paick JS, Chun YS. HIF-1alpha promotes survival of prostate cells at a high zinc environment. Prostate 67, 1514-1523 (2007).
33. Yun YJ, Li SH, Cho YS, Park JW, Chun YS. Survivin mediates prostate cell protection by HIF-1alpha against zinc toxicity. Prostate 70, 1179-1188 (2010).
34. Mao X, Schimmer AD. The toxicology of clioquinol. Toxicol. Lett. 182, 1-6 (2008).
35. Bareggi SR, Cornelli U. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci. Ther. doi:10.1111/j.1755-5949. 2010.00231.x (2010) (Epub ahead of print).
36. Lemire J, Mailloux R, Appanna VD. Zinc toxicity alters mitochondrial metabolism and leads to decreased ATP production in hepatocytes. J. Appl. Toxicol. 28, 175-182 (2008).
37. Xu J, Xu Y, Nguyen Q, Novikoff PM, Czaja MJ. Induction of hepatoma cell apoptosis by c-myc requires zinc and occurs in the absence of DNA fragmentation. Am. J. Physiol. 270, G60-G70 (1996).
38. Donadelli M, Dalla PE, Scupoli MT, Costanzo C, Scarpa A, Palmieri M. Intracellular zinc increase inhibits p53-/-pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. Biochim. Biophys. Acta 1793, 273-280 (2009).
39. Bae SN, Lee YS, Kim MY, Kim JD, Park LO. Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR®) on human epithelial ovarian cancer cell line, OVCAR-3. Gynecol. Oncol. 103, 127-136 (2006).
40. Ding WQ, Yu HJ, Lind SE. Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett. 271, 251-259 (2008).
41. Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 44, 5390-5394 (1984).
42. Santoliquido PM, Southwick HW, Olwin JH. Trace metal levels in cancer of the breast. Surg. Gynecol. Obstet. 142, 65-70 (1976).
43. Margalioth EJ, Schenker JG, Chevion M. Copper and zinc levels in normal and malignant tissues. Cancer 52, 868-872 (1983).
44. Farquharson MJ, Al-Ebraheem A, Geraki K, Leek R, Jubb A, Harris AL. Zinc presence in invasive ductal carcinoma of the breast and its correlation with oestrogen receptor status. Phys. Med. Biol. 54, 4213-4223 (2009).
45. Lopez V, Foolad F, Kelleher SL. ZnT2-overexpression represses the cytotoxic effects of zinc hyper-accumulation in malignant metallothionein-null T47D breast tumor cells. Cancer Lett. 304, 41-51 (2011).
46. Doerr TD, Prasad AS, Marks SC et al. Zinc deficiency in head and neck cancer patients. J. Am. Coll. Nutr. 16, 418-422 (1997).
47. Franklin RB, Costello LC. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch. Biochem. Biophys. 463, 211-217 (2007).